As it has been reported that YAP activation is a critical factor for BRAF inhibitor resistance in BRAF-mutant cancer cells5,6 and that the inhibition of the PI3K/AKT pathway is a key mechanism to overcome BRAF inhibitor resistance in BRAF-mutant colon cancer cells26,27, we subsequently examined the possibility that miR-550a-3-5p treatment could overcome BRAF inhibitor resistance through the inhibition of AKT activity in BRAF inhibitor-resistant colon cancer and melanoma cells. The gene discussed is AKT1; the disease is melanoma.